Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pharming (PHAR) Income from Continuing Operations (2020 - 2025)

Historic Income from Continuing Operations for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to $25.0 million.

  • Pharming's Income from Continuing Operations rose 27524.04% to $25.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.4 million, marking a year-over-year increase of 15647.29%. This contributed to the annual value of -$12.0 million for FY2024, which is 20512.36% down from last year.
  • Pharming's Income from Continuing Operations amounted to $25.0 million in Q3 2025, which was up 27524.04% from $9.4 million recorded in Q2 2025.
  • Pharming's Income from Continuing Operations' 5-year high stood at $25.6 million during Q2 2021, with a 5-year trough of -$22.5 million in Q2 2024.
  • Its 5-year average for Income from Continuing Operations is $1.6 million, with a median of $3.0 million in 2022.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first crashed by 28390.75% in 2021, then surged by 2476194.35% in 2022.
  • Over the past 5 years, Pharming's Income from Continuing Operations (Quarter) stood at $15.2 million in 2021, then crashed by 63.57% to $5.5 million in 2022, then crashed by 223.82% to -$6.9 million in 2023, then increased by 10.86% to -$6.1 million in 2024, then skyrocketed by 508.97% to $25.0 million in 2025.
  • Its last three reported values are $25.0 million in Q3 2025, $9.4 million for Q2 2025, and -$3.9 million during Q1 2025.